March 10 (Reuters) -
BioNTech SE <22UAy.DE>::
*EXPECTS 2025 TOTAL REVENUES BETWEEN EUR 1.7 BILLION AND EUR 2.2 BILLION
*CASH AND CASH EQUIVALENTS PLUS SECURITY INVESTMENTS OF EUR 17.4 BILLION AS OF DECEMBER 31, 2024
*CEO - EXPECT 2025 TO BE A DATA-RICH YEAR WITH MULTIPLE IMPORTANT UPDATES FROM OUR PRIORITY PROGRAMS, WHICH WE BELIEVE HAVE DISRUPTIVE POTENTIAL AND COULD IMPROVE STANDARD OF CARE, IF SUCCESSFULLY DEVELOPED AND APPROVED
*OUTLOOK 2025: RESEARCH AND DEVELOPMENT EXPENSES EUR 2,600 MILLION - EUR 2,800 MILLION, SG&A EXPENSES EUR 650 MILLION - EUR 750 MILLION
*OUTLOOK 2025: CAPITAL EXPENDITURES FOR OPERATING ACTIVITIES EUR 250 MILLION - EUR 350 MILLION
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 10-MAR-202510:55:00.233 GMT
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。